skip to navigation
skip to content
Search
About us
Who we are
Horizon scanning
Public involvement
Public Involvement Network Advisory Group
Patient group partners
Public partners
Policies & publications
Minutes
Meetings
Register for a meeting
ILAP
Latest update
HIS website survey
Speeding up access to new medicines in Scotland: abbreviated process
International Collaboration
Joint statement: NICE and SMC/HIS collaboration
NICE draft recommendations published on the use of treatments for COVID-19
Healthcare Improvement Scotland
NICE and SMC/HIS collaboration on health technology appraisal of therapeutics for COVID-19
Her Majesty Queen Elizabeth II
April 2022 decisions news release
New access tool launched as part of SMC’s joint work on streamlining patient access to innovative medicines
December 2021 decisions news release
November 2021 decisions news release
March 2023 decisions news release
SMC publishes a Collaborative Advice Document for treatments for COVID-19
Public Partner Advert
Fast Track Resubmission Process
NICE issues final draft guidance for nirmatrelvir plus ritonavir for treating COVID-19 (partial review of TA878)
SMC publishes an updated Collaborative Advice Document for COVID-19 medicines
NICE issues final draft guidance on multiple technology appraisal (MTA), ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor– ivacaftor for treating cystic fibrosis.
SMC publishes Collaborative Advice Documents for ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis.
Contact us
Medicines advice
How we decide
PACE
Interim acceptance decision option
Ultra-orphan medicines for extremely rare conditions
Abbreviated submissions
Making a submission
somapacitan (Sogroya)
Home
/
Medicines advice
/
somapacitan (Sogroya)
Medicine details
Medicine name:
somapacitan (Sogroya)
SMC ID:
SMC2629
Pharmaceutical company
Novo Nordisk Ltd
BNF chapter
Endocrine system
Submission type
Abbreviated
Publication due date:
TBC
Back to Medicines Advice
